01713nas a2200361   4500000000100000008004100001260001300042653001200055653002300067653001000090653002100100653001100121653001800132653001200150653001800162653001800180653001700198100001700215700001300232700001300245700001400258700001500272700001800287700001200305700001100317700001300328700001400341245009300355300001100448490000600459520087200465022001401337       1990                            d  c1990 Dec10aAnimals10aBacterial Vaccines10aChild10aChild, Preschool10aHumans10aImmunotherapy10aleprosy10aMycobacterium10aPremedication10aTuberculosis1 aStanford J L1 aRook G A1 aBahr G M1 aDowlati Y1 aGanapati R1 aGhazi Saidi K1 aLucas S1 aRamu G1 aTorres P1 aMinh Ly H00aMycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.  a525-300 v83 a<p>Both leprosy and tuberculosis present continuing problems in their control, especially in the developing world, despite the availability of drugs effective in producing a bacteriological cure. Improved immunoprophylaxis, and an effective immunotherapy to be used with chemotherapy are urgently required. Intradermal injection of a suspension of killed Mycobacterium vaccae promotes cell-mediated responses to antigens common to all mycobacteria, and switches off the tissue-necrotizing aspects of the Koch phenomenon. These properties led to the use of the suspensions as an improved vaccine, either alone or in combination with BCG. The same properties led to the employment of the suspension in immunotherapy as an adjunct to chemotherapy in the treatment of both leprosy and tuberculosis. The evidence leading to these conclusions is reviewed and discussed.</p>  a0264-410X